Ovid Therapeutics Inc.
General ticker "OVID" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $51.7M (TTM average)
Ovid Therapeutics Inc. follows the US Stock Market performance with the rate: 48.6%.
Estimated limits based on current volatility of 2.3%: low 2.64$, high 2.77$
Factors to consider:
- Earnings expected soon, date: 2026-05-12 bmo
- Total employees count: 23 (-42.5%) as of 2024
- Top business risk factors: Insufficient funding, Profitability concerns, Drug development risks, Economic downturns and volatility, Regulatory and compliance
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.09$, 2.56$]
- 2026-12-31 to 2027-12-31 estimated range: [0.97$, 2.22$]
Financial Metrics affecting the OVID estimates:
- Positive: with PPE of -5.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -31.78 <= 0.07
- Positive: Shareholder equity ratio, % of 86.57 > 64.25
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
Short-term OVID quotes
Long-term OVID plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.39MM | $0.57MM | $7.25MM |
| Operating Expenses | $59.67MM | $62.45MM | $49.69MM |
| Operating Income | $-59.28MM | $-61.88MM | $-42.44MM |
| Non-Operating Income | $6.94MM | $35.45MM | $25.02MM |
| R&D Expense | $28.59MM | $36.77MM | $25.58MM |
| Income(Loss) | $-52.34MM | $-26.43MM | $-17.41MM |
| Profit(Loss)* | $-52.34MM | $-26.43MM | $-17.41MM |
| Stockholders Equity | $87.80MM | $68.23MM | $130.66MM |
| Assets | $144.03MM | $92.17MM | $150.93MM |
| Operating Cash Flow | $-45.78MM | $-55.96MM | $-38.33MM |
| Capital expenditure | $0.14MM | $0.07MM | $0.00MM |
| Investing Cash Flow | $-2.58MM | $54.59MM | $-49.85MM |
| Financing Cash Flow | $30.54MM | $0.62MM | $75.21MM |
| Earnings Per Share** | $-0.74 | $-0.37 | $-0.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.